scholarly journals Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients

2020 ◽  
Vol 22 (5) ◽  
Author(s):  
Giada Pietrosi ◽  
Giovanna Russelli ◽  
Floriana Barbera ◽  
Gabriele Curcio ◽  
Fabio Tuzzolino ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Hcv Rna ◽  
Direct Acting Antivirals ◽  
Transplant Patients ◽  
Direct Acting

Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals

2014 ◽  
Vol 35 ◽  
pp. 44-50 ◽  
Author(s):  
Audrey Coilly ◽  
Bruno Roche ◽  
Jean-Charles Duclos-Vallée ◽  
Didier Samuel
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Direct Acting Antivirals ◽  
Optimal Therapy ◽  
Transplant Patients ◽  
Direct Acting

P1652IMPACT OF HEPATITIS C VIRUS AND DIRECT ACTING ANTIVIRALS ON JAPANESE RENAL ALLOGRAFT RECIPIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Kazuaki Okino ◽  
Keita Yamazaki ◽  
Keiichiro Okada ◽  
Keiji Fujimoto ◽  
HIROKI ADACHI ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Allograft ◽  
Patient Survival ◽  
Hcv Infection ◽  
Hcv Rna ◽  
Direct Acting Antivirals ◽  
Group A ◽  
Group B ◽  
Direct Acting ◽  
The Impact

Abstract Background and Aims The impact of hepatitis C virus (HCV) infection on patient survival after renal transplantation was worse. Previously, we found that continuous HCV infection was a significant independent risk factor for actuarial survival (especially at ≥20 years after the transplant procedure) among Japanese renal allograft recipients. This study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient outcomes in renal allograft recipients. Method We studied 46 cases (28 males, 18 females; 37 living-donor cases, 9 deceased-donor cases; mean follow-up period 305 months ranging from 2 to 420 months) out of the 315 renal transplanted patients who underwent the first renal transplantation in Kanazawa Medical University since 1974. They had antibodies against HCV: 11 were positive for HCV RNA and received DAAs (Group A, all of them genotype 1b); 27 were HCV RNA positive and did not receive any treatment (Group B); 8 were negative for HCV RNA (Group C) (Fig.1). Results All Group A patients had HCV RNA negativity after 2-12 weeks of treatment started, and 11 (100%) achieved a sustained virological response (SVR) at 24 weeks. All of them had no adverse effects by the use of DAAs. In this cohort, no patients in Group A died. On the other hand, 15 (55.5％) of 27 in Group B and 3 (37.5%) of 8 in Group C died. Causes of death among Group B were liver cirrhosis (5 cases), hepatocellular carcinoma (2 case), infections complicated with chronic hepatitis (6 cases) in chronic phase, fibrosing cholestatic hepatitis due to HCV (1 case) after surgery, and cardiovascular disease (1 case). The patient survival rate was significantly higher in Group A patients who received DAAs by Kaplan- Meier life table method (Log Rank test, Kay-square 11.7, p=0.004) (Fig.2). Conclusion Our results support the notion that continuous HCV infection was a harmful and that new DAAs were efficient and safe to treat HCV infection after renal transplantation.

Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States

Hepatology ◽  
2017 ◽  
Vol 66 (1) ◽  
pp. 46-56 ◽  
Author(s):  
Aijaz Ahmed ◽  
Stevan A. Gonzalez ◽  
George Cholankeril ◽  
Ryan B. Perumpail ◽  
Justin McGinnis ◽  
...  
Keyword(s):  
United States ◽  
Liver Transplant ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Cost Effective ◽  
The United States ◽  
Direct Acting Antivirals ◽  
Cost Effective Treatment ◽  
Direct Acting

scholarly journals Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

Biomedicines ◽  
2020 ◽  
Vol 8 (6) ◽  
pp. 175
Author(s):  
Sara Kishta ◽  
Ashraf Tabll ◽  
Tea Omanovic Kolaric ◽  
Robert Smolic ◽  
Martina Smolic
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Dna Ploidy ◽  
Hcv Rna ◽  
Direct Acting Antivirals ◽  
Hepatic Cells ◽  
Chronic Hcv ◽  
Direct Acting

Although hepatitis C virus (HCV) RNA may be eliminated from blood circulation by direct-acting antivirals (DAA) therapy as assessed by real-time polymerase chain reaction (PCR), HCV RNA can still be present in liver tissue, and this is known as occult HCV. There has been a lot of controversy surrounding the recurrence of hepatocellular carcinoma (HCC) after DAA treatment of hepatic cells infected with chronic HCV. One of the main risk factors that leads to de novo HCC is the chronicity of HCV in hepatic cells. There are many studies regarding the progression of HCV-infected hepatic cells to HCC. However, there is a lack of research on the different molecular mechanisms that lead to the progression of chronic HCV infection to HCC, as well as on the effect of HCV on the alteration of DNA ploidy, which eventually leads to a recurrence of HCC after DAA treatment. In this review article, we will address some risk factors that could lead to the development/recurrence of HCC after treatment of HCV with DAA therapy, such as the role of liver cirrhosis, the alteration of DNA ploidy, the reactivation of hepatitis B virus (HBV), the role of cytokines and the alteration of the immune system, concomitant non- alcoholic fatty liver disease (NAFLD), obesity, alcohol consumption and also occult HCV infection/co-infection. Clinicians should be cautious considering that full eradication of hepatocarcinogenesis cannot be successfully accomplished by anti-HCV treatment alone.

scholarly journals A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS?

2018 ◽  
Vol 1 (suppl_1) ◽  
pp. 305-306
Author(s):  
S Almarzooqi ◽  
M van Tilborg ◽  
R Maan ◽  
J Vermehren ◽  
B Maasoumy ◽  
...  
Keyword(s):  
Core Antigen ◽  
Hcv Rna ◽  
Direct Acting Antivirals ◽  
Hcv Core Antigen ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document